Publication:
Coronavac covid-19 vaccine-induced anaphylaxis: Clinical characteristics and revaccination outcomes

Simple item page
dc.contributor.authorWannada Laisuanen_US
dc.contributor.authorChamard Wongsaen_US
dc.contributor.authorChirawat Chiewchalermsrien_US
dc.contributor.authorTorpong Thongngarmen_US
dc.contributor.authorTicha Rerkpattanapipaten_US
dc.contributor.authorPansa Iamrahongen_US
dc.contributor.authorChulapha Ruangwattanachoken_US
dc.contributor.authorSira Nanthapisalen_US
dc.contributor.authorMongkhon Sompornrattanaphanen_US
dc.contributor.otherRamathibodi Hospitalen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherFaculty of Medicine, Thammasat Universityen_US
dc.contributor.otherSrinakharinwirot Universityen_US
dc.date.accessioned2022-08-04T11:04:57Z
dc.date.available2022-08-04T11:04:57Z
dc.date.issued2021-01-01en_US
dc.description.abstractAnaphylaxis to CoronaVac, an inactivated vaccine against COVID-19, is extremely rare. We report 12 cases of anaphylaxis after CoronaVac administration, focusing on clinical characteristics and management outcomes. Skin test and graded vaccine challenge were successfully performed in our cases and might be considered if an inactivated vaccine is the only remaining option.en_US
dc.identifier.citationJournal of Asthma and Allergy. Vol.14, (2021), 1209-1215en_US
dc.identifier.doi10.2147/JAA.S333098en_US
dc.identifier.issn11786965en_US
dc.identifier.other2-s2.0-85118542385en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/78576
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118542385&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCoronavac covid-19 vaccine-induced anaphylaxis: Clinical characteristics and revaccination outcomesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85118542385&origin=inwarden_US

Files

Collections

Scopus 2021